Akebia Therapeutics (AKBA) Non-Current Assets (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Non-Current Assets data on file, last reported at $119.0 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $119.0 million, up 11.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $459.4 million (up 7.25% YoY), and the FY2025 annual result was $123.6 million, up 15.7% from the prior year.
• Non-Current Assets slipped to $119.0 million in Q1 2026 per AKBA's latest filing, from $123.6 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $236.7 million in Q1 2022 and troughed at $105.8 million in Q3 2025.
• A 5-year average of $139.8 million and a median of $123.6 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets slumped 38.97% in 2023, then increased 15.7% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $170.9 million in 2022, then dropped by 27.69% to $123.6 million in 2023, then slipped by 13.53% to $106.8 million in 2024, then climbed by 15.7% to $123.6 million in 2025, then decreased by 3.7% to $119.0 million in 2026.
• Business Quant data shows AKBA's Non-Current Assets at $119.0 million in Q1 2026, $123.6 million in Q4 2025, and $105.8 million in Q3 2025.